10-Q: Halozyme Q3 2025: Royalty Surge & Elektrofi Acquisition

Halozyme Therapeutics reports robust Q3 2025 financial results driven by strong royalty growth and announces the strategic acquisition of Elektrofi, expanding its drug delivery technology portfolio.

Summary

• Net income for the three months ended September 30, 2025, increased by 27.9% to $175.2 million, up from $137.0 million in the prior year period.
• Total revenues for Q3 2025 grew by 22.1% to $354.3 million, compared to $290.1 million in Q3 2024.
• Royalty revenues surged by 52.2% to $236.0 million in Q3 2025, primarily driven by increased sales of VYVGART Hytrulo, DARZALEX SC, and Phesgo.
• For the nine months ended September 30, 2025, net income rose by 49.3% to $458.5 million, and total revenues increased by 31.7% to $944.8 million.
• The company announced the acquisition of Elektrofi, Inc., a biopharmaceutical company with ultra-high concentration microparticle technology, for $750 million in upfront consideration and up to three $50 million milestone payments.
• Halozyme initiated the third $250 million share repurchase tranche under its $750 million approved program from February 2024, having used $92.3 million to repurchase approximately 1.7 million shares as of September 30, 2025.
• The FDA issued a Complete Response Letter for Janssen's Biologics License Application for amivantamab SC, citing observations related to a third-party drug product manufacturing site.
• argenx received approval from Japan's Ministry of Health, Labour and Welfare for VYVDURA prefilled syringe for self-injection for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
• Janssen received European Commission approval for a new indication for DARZALEX SC as a monotherapy for adult patients with high-risk smoldering multiple myeloma.
• The conditional conversion feature of the 2028 Convertible Notes was triggered, resulting in their classification as a current portion of long-term debt.

Sentiment

Score: 8

Explanation: Halozyme Therapeutics delivered exceptional financial results for Q3 and the nine months ended September 30, 2025, with substantial growth in royalties, total revenue, and net income. The ENHANZE technology continues to drive significant value through numerous successful partner products and new approvals. The strategic acquisition of Elektrofi's Hypercon technology positions the company for future innovation and market expansion in drug delivery. The ongoing share repurchase program demonstrates a commitment to returning value to shareholders. While regulatory setbacks for partner products and patent litigation present some risks, the overall strong financial performance, robust pipeline, and strategic growth initiatives make Halozyme an attractive investment. The reclassification of convertible notes to current liabilities is a known event and manageable given the company's strong liquidity.

Positives

• Net income increased significantly by 27.9% to $175.2 million for Q3 2025 and by 49.3% to $458.5 million for the nine months ended September 30, 2025.
• Total revenues grew by 22.1% in Q3 2025 and 31.7% for the nine months, demonstrating strong top-line performance.
• Royalty revenue experienced a substantial 52.2% increase for both Q3 and the nine months, driven by key partner products like VYVGART Hytrulo, DARZALEX SC, and Phesgo.
• Proprietary product sales, primarily XYOSTED, increased by 31% in Q3 and 13% year-to-date due to continued market penetration.
• The acquisition of Elektrofi, Inc. for $750 million upfront plus potential milestones, strategically enhances the company's drug delivery technology portfolio with ultra-high concentration microparticle technology.
• argenx received regulatory approval in Japan for VYVDURA prefilled syringe for self-injection, expanding market access for an ENHANZE-enabled product.
• Janssen secured European Commission approval for a new indication for DARZALEX SC, broadening its market for an ENHANZE-enabled therapy.
• Net cash provided by operating activities increased by $131.9 million for the nine months ended September 30, 2025, indicating strong operational cash generation.
• The company is actively executing a share repurchase program, having initiated the third $250 million tranche and repurchased 1.7 million shares for $92.3 million as of September 30, 2025, returning value to shareholders.
• Cash, cash equivalents, and marketable securities totaled $702.0 million as of September 30, 2025, providing strong liquidity.

Negatives

• Revenues under collaborative agreements decreased by 50% in Q3 2025 and 12% for the nine months, primarily due to the timing of milestone achievements.
• Device partnered product sales declined by 38% in Q3 2025 and 6% for the nine months, attributed to fluctuations in partner demand.
• Investment and other income, net, decreased by 18% in Q3 2025, primarily due to lower market interest rates.
• Otter Pharmaceuticals discontinued marketing OTREXUP and terminated its supply agreement in Q4 2025, impacting a device partnered product.
• Chugai Pharmaceutical Co., Ltd. terminated its ENHANZE program for an undisclosed target, indicating a pipeline setback.
• The FDA issued a Complete Response Letter for Janssen's Biologics License Application for amivantamab SC, citing observations at a third-party manufacturing facility, which will delay its approval.
• The FDA also published a Complete Response Letter to a New Drug Application for ATRS-1902, citing observations related to a third-party drug product manufacturing site, indicating a delay for a proprietary product candidate.
• Litigation costs of $6.0 million were incurred in Q3 2025 in connection with a patent infringement lawsuit against Merck Sharp & Dohme Corp., increasing SG&A expenses.
• The 2028 Convertible Notes' conditional conversion feature was triggered, reclassifying $710.7 million to current portion of long-term debt, which represents a significant near-term liability.

Risks

• Uncertainty in obtaining and maintaining patent protection for products and technologies, which may not provide commercially significant exclusivity.
• Risk that others may independently develop similar technologies or obtain patent protection before the company.
• Potential for existing patents to be challenged, limited in scope, or deemed invalid/unenforceable, which could materially adversely affect business and financial condition.
• Patent infringement litigation, such as the lawsuit against Merck, can be costly, time-consuming, and divert management's attention, potentially resulting in substantial damages or injunctions.
• Adverse decisions in patent proceedings (e.g., European Patent Office revoking Janssen's DARZALEX SC patents) could lead to permanent loss of contested patent rights.
• Reliance on trade secrets and unpatented proprietary know-how carries risks of ownership disputes or enforceability challenges of confidentiality agreements.
• Challenges in obtaining trademark protection for product names or delays in regulatory approval of product names could delay product launches.
• Rising healthcare costs and cost containment pressures from third-party payers and government policies (e.g., Medicare, Affordable Care Act) could lead to lower product prices and reduced revenue.
• Changes in federal reimbursement policy, including executive actions, regulations, or demonstration projects by CMS, could significantly affect drug coverage and reimbursement.
• The May 2025 Executive Order calling for voluntary price reductions and potential Most Favored Nations (MFN) pricing could negatively impact U.S. pharmaceutical prices.
• Legislative proposals, such as the Inflation Reduction Act of 2022, could affect access to and revenue from partner products, allow federal price negotiations, or permit drug importation.
• Uncertainty regarding the application of IRA price controls to combination therapies like ENHANZE products, with CMS needing more time to develop objective policy criteria for 2029 onwards.
• Aggressive state legislation and regulations designed to control pharmaceutical product pricing could negatively impact revenues and financial condition.
• Consolidation in the payer space (PBMs, insurers) may lead to increased pressure for higher discounts and rebates, limiting patient access and utilization.
• Risks associated with discount, rebate, and co-pay coupon programs, including potential lawsuits, changes in insurer policies, or new legislation/regulatory actions.
• Inaccurate reporting of pricing data could lead to substantial fines, penalties, or additional rebates/discounts.
• Workforce reductions at federal health agencies, including the FDA, could delay regulatory approval processes.
• Changes in U.S. trade policy, including tariffs and potential countermeasures, could increase costs, disrupt global supply chains, and create market uncertainty.

Future Outlook

We anticipate continued growth in royalty revenue driven by increasing partner product sales of DARZALEX SC, Phesgo, VYVGART Hytrulo, and recently launched ENHANZE partner products like TECENTRIQ SC, OCREVUS SC, RYBREVANT SC, and Opdivo Qvantig. Modest price erosion is expected to persist for earlier-launched ENHANZE products such as Herceptin and MabThera. Proprietary product sales are projected to grow as market share in the testosterone replacement therapy market expands. Revenues from collaborative agreements are expected to fluctuate based on partners' achievement of clinical, regulatory, and event-based milestones, and the ability to secure new agreements. We believe current cash resources, anticipated revenues, and potential future financing activities will be sufficient to fund operations for at least the next 12 months. CMS intends to further consider policy for fixed combination drugs under IRA price controls for initial price applicability year 2029.

Management Comments

• We expect royalty revenue to grow further as a result of anticipated increasing partner product sales of DARZALEX SC, Phesgo and VYVGART Hytrulo, and sales of recently launched ENHANZE partner products, TECENTRIQ SC and OCREVUS SC by Roche, RYBREVANT SC by Janssen and Opdivo Qvantig by BMS.
• We expect modest price erosion to continue on earlier launched ENHANZE partner products, Herceptin and MabThera.
• We expect sales of our proprietary products will grow in future years as we continue to gain market share in the testosterone replacement therapy market.
• We expect product sales of bulk rHuPH20 and device partnered products to fluctuate in future periods based on the needs of our partners.
• We expect these revenues [under collaborative agreements] to continue to fluctuate in future periods based on our partners ability to meet various clinical, regulatory and event-based milestones set forth in such agreements and our ability to obtain new collaborative agreements.
• We believe that our current cash, cash equivalents and marketable securities will be sufficient to fund our operations for at least the next 12 months.
• Janssen has indicated they are working closely with the FDA to bring SC amivantamab to patients as quickly as possible.

Industry Context

The biopharmaceutical industry is increasingly prioritizing patient convenience and reduced treatment burden, a trend directly addressed by Halozyme's ENHANZE drug delivery technology, which facilitates subcutaneous administration of high-dose biologics. The strategic acquisition of Elektrofi's ultra-high concentration microparticle technology positions Halozyme to expand its leadership in advanced drug delivery solutions, potentially enabling new therapies for challenging formulations. The industry continues to face significant pricing pressures from government regulations, such as the Inflation Reduction Act, and private payers, which could impact the profitability of both Halozyme's and its partners' products. Regulatory hurdles, exemplified by the FDA's Complete Response Letter for Janssen's amivantamab SC, underscore the stringent approval environment and the potential for delays even for promising candidates. Despite these challenges, the continued expansion of ENHANZE partnerships and product approvals across diverse therapeutic areas highlights the technology's strong value proposition and market acceptance.

Comparison to Industry Standards

• ENHANZE technology significantly reduces administration times for biologics, offering a competitive advantage in patient convenience compared to traditional intravenous (IV) infusions. For example, Herceptin SC is administered in 2-5 minutes versus 30-90 minutes IV, and DARZALEX FASPRO in 3-5 minutes versus multi-hour IV infusions.
• The technology enables fixed-dose subcutaneous dosing, potentially extending dosing intervals and reducing infusion-related reactions, which are key improvements over many existing IV and some subcutaneous therapies in the market.
• Certain ENHANZE co-formulated proprietary drugs have received additional exclusivity, extending their patent life beyond the IV drug's expiry, providing a strategic intellectual property advantage over standard drug development approaches.
• The acquisition of Elektrofi's Hypercon technology for ultra-high concentration microparticles positions Halozyme to address biologics that are difficult to formulate for subcutaneous delivery, expanding its competitive edge beyond its core rHuPH20 enzyme.
• The FDA's Complete Response Letter for Janssen's amivantamab SC due to manufacturing observations is a common industry challenge, reflecting the rigorous regulatory landscape and the importance of manufacturing quality in biopharmaceutical product approvals, aligning with typical industry setbacks.

Legal Proceedings

• Filed a patent infringement lawsuit against Merck Sharp & Dohme Corp. in April 2025 in the U.S. District Court in New Jersey, alleging infringement of Halozyme's MDASE subcutaneous drug delivery technology by Merck's SC Keytruda, seeking damages and injunctive relief.
• The Opposition Division of the European Patent Office revoked two of Janssen's co-formulation patents for DARZALEX SC in March 2023 and October 2024.

Stakeholder Impact

• Shareholders are positively impacted by strong financial performance, increased EPS, and the ongoing share repurchase program, which enhances shareholder value. The strategic acquisition also offers long-term growth potential.
• Patients benefit from improved drug delivery solutions, such as shorter administration times and potential for home administration, enhancing convenience and reducing treatment burden for ENHANZE-enabled therapies.
• Partners (e.g., Roche, Janssen, argenx, BMS) continue to benefit from the ENHANZE technology's ability to improve drug profiles and expand market reach, as evidenced by new product approvals and expanded indications.
• Employees may experience shifts in resource allocation and labor initiatives, as mentioned in R&D and SG&A expense explanations, while also benefiting from share-based compensation programs.
• Creditors face a reclassification of $710.7 million of 2028 Convertible Notes to current liabilities, indicating a near-term obligation, though the company's strong cash position and operating cash flow suggest capacity to manage this.

Next Steps

• Complete the acquisition of Elektrofi in the fourth quarter of 2025, pending antitrust review and customary closing conditions.
• Janssen will work closely with the FDA to address manufacturing facility observations to advance the Biologics License Application for amivantamab SC.
• Continue to gain market share in the testosterone replacement therapy market with proprietary products like XYOSTED.
• Evaluate next steps for the Pfizer QuickShot auto-injector program.
• CMS intends to continue to consider the appropriate policy for fixed combination drugs under IRA price controls in rulemaking beginning in initial price applicability year 2029.
• Quarterly assessment of the need for valuation allowance on deferred tax assets.
• Continue evaluating the impact of ASU 2024-03 on consolidated financial statements and disclosures.
• Pursue new collaborative agreements and expand existing relationships to further leverage ENHANZE technology.
• Continue share repurchases under the approved capital return program.

Key Dates

Recommendation

Halozyme Therapeutics has demonstrated exceptional financial performance in Q3 and year-to-date 2025, with significant growth in revenue and net income, primarily fueled by robust royalty streams from its ENHANZE technology. The strategic acquisition of Elektrofi's Hypercon technology is a forward-looking move that strengthens the company's competitive position in advanced drug delivery. The ongoing share repurchase program underscores management's confidence and commitment to shareholder returns. While regulatory delays for partner products and ongoing patent litigation introduce some risks, the fundamental business drivers, strong liquidity, and expanding pipeline of ENHANZE-enabled therapies present a compelling investment case for substantial long-term value creation.

Keywords

Biopharmaceutical, Drug delivery, ENHANZE, rHuPH20, Subcutaneous injection, Auto-injector, Elektrofi, Hypercon, Royalty revenue, SEC filing, 10-Q, Financial results, Biotech, Acquisition, Patent litigation, Share repurchase, Oncology, Immunology, Rare diseases, Corporate governance, Convertible notes